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R. Das, J.M. Miller, and S. Schnyder Ghamloush, for the KidCOVE Study Group*

A BS T R AC T
BACKGROUND

Vaccination of children to prevent coronavirus disease 2019 (Covid-19) is an urgent
public health need. The safety, immunogenicity, and efficacy of the mRNA-1273
vaccine in children 6 to 11 years of age are unknown.
METHODS

Part 1 of this ongoing phase 2–3 trial was open label for dose selection; part 2 was an
observer-blinded, placebo-controlled expansion evaluation of the selected dose. In part
2, we randomly assigned children (6 to 11 years of age) in a 3:1 ratio to receive two
injections of mRNA-1273 (50 μg each) or placebo, administered 28 days apart. The
primary objectives were evaluation of the safety of the vaccine in children and the
noninferiority of the immune response in these children to that in young adults (18 to
25 years of age) in a related phase 3 trial. Secondary objectives included determination
of the incidences of confirmed Covid-19 and severe acute respiratory syndrome coronavirus 2 infection, regardless of symptoms. Interim analysis results are reported.

The authors’ full names, academic degrees, and affiliations are listed in the Appendix. Dr. Schnyder Ghamloush can be
contacted at sabine.schnyder.ghamloush@
modernatx.com or at Moderna, 200 Technology Sq., Cambridge, MA 02139.
*A list of the KidCOVE Study Group members is provided in the Supplementary
Appendix, available at NEJM.org.
This article was published on May 11, 2022,
at NEJM.org.
DOI: 10.1056/NEJMoa2203315
Copyright © 2022 Massachusetts Medical Society.

RESULTS

In part 1 of the trial, 751 children received 50-μg or 100-μg injections of the mRNA1273 vaccine, and on the basis of safety and immunogenicity results, the 50-μg dose
level was selected for part 2. In part 2 of the trial, 4016 children were randomly assigned to receive two injections of mRNA-1273 (50 μg each) or placebo and were
followed for a median of 82 days (interquartile range, 14 to 94) after the first injection.
This dose level was associated with mainly low-grade, transient adverse events, most
commonly injection-site pain, headache, and fatigue. No vaccine-related serious adverse events, multisystem inflammatory syndrome in children, myocarditis, or pericarditis were reported as of the data-cutoff date. One month after the second injection
(day 57), the neutralizing antibody titer in children who received mRNA-1273 at a
50-μg level was 1610 (95% confidence interval [CI], 1457 to 1780), as compared with
1300 (95% CI, 1171 to 1443) at the 100-μg level in young adults, with serologic responses in at least 99.0% of the participants in both age groups, findings that met the
prespecified noninferiority success criterion. Estimated vaccine efficacy was 88.0%
(95% CI, 70.0 to 95.8) against Covid-19 occurring 14 days or more after the first injection, at a time when B.1.617.2 (delta) was the dominant circulating variant.
CONCLUSIONS

Two 50-μg doses of the mRNA-1273 vaccine were found to be safe and effective in
inducing immune responses and preventing Covid-19 in children 6 to 11 years of age;
these responses were noninferior to those in young adults. (Funded by the Biomedical
Advanced Research and Development Authority and the National Institute of Allergy
and Infectious Diseases; KidCOVE ClinicalTrials.gov number, NCT04796896.)
n engl j med  nejm.org
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he Coronavirus Efficacy (COVE) and
Teen COVE trials1-3 showed that the mRNA1273 vaccine (Moderna) had mainly lowgrade transient adverse effects and high efficacy
in preventing symptomatic coronavirus disease
2019 (Covid-19) in persons who were 12 years of
age or older, and mRNA-1273 is approved for
vaccination of adults in the United States. Although the highest risk of illness and death from
Covid-19 occurs among older adults and populations with underlying coexisting conditions,4
children are at risk for severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection
that can lead to severe Covid-19–related outcomes,
including hospitalization, the use of life-supporting interventions, and death.5,6 The burden of
Covid-19 in children extends to social issues such
as school interruptions and other life disruptions
that may result in long-term consequences for
academic development and well-being.7 Complications of SARS-CoV-2 infection in children and
adolescents can include the development of multisystem inflammatory syndrome in children
(MIS-C) and sequelae such as long Covid-198-10;
these outcomes indicate a compelling need to protect children through vaccination.
Previous studies have shown that vaccination
of 12-to-17-year-old adolescents reduced the risks
of MIS-C and hospitalization.5,11,12 The Covid-19
BNT162b2 vaccine (Pfizer–BioNTech) received
emergency use authorization (EUA) from the Food
and Drug Administration (FDA) for immunization of adolescents and children 5 to 11 years of
age.13 Recently, the mRNA-1273 vaccine received
provisional approval in some countries outside
the United States for use in children who are 6 to
11 years of age.14-16 Here, we report the interim
results of the ongoing phase 2–3 KidCOVE trial,
which evaluated the safety, immunogenicity, and
efficacy of two 50-μg doses of the mRNA-1273
vaccine, as compared with placebo, administered
28 days apart in children who were 6 to 11 years
of age.

Me thods
Trial Oversight and Participants

The trial participants in three age cohorts (6 to 11
years, 2 to 5 years, and 6 months to 23 months)
were enrolled at 79 sites in the United States and
8 sites in Canada. The trial was conducted in two
parts, with an open-label dose-selection phase in
2
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part 1 and an observer-blinded, randomized,
placebo-controlled expansion phase in part 2,
which assessed safety, immunobridging (an approach in which the immune response in the
test population is compared with that in a population in which efficacy has been shown), and
efficacy. Here, we report the results of the interim analysis of part 1 and part 2 of the trial in
the cohort of 6-to-11-year-old children. After the
EUA for the BNT162b2 vaccine was updated on
October 29, 2021, to include children 5 to 11 years
of age in the United States, participants became
eligible to have their data unblinded and placebo
recipients became eligible to cross over to receive
the mRNA-1273 vaccine. The cutoff date for blinded data was November 10, 2021.
Eligible children were generally healthy, but
children with stable chronic conditions were also
included. Children with a known recent history
of SARS-CoV-2 infection, those who had received
an investigational or approved SARS-CoV-2–related vaccine, and those with known hypersensitivity
to vaccine components or excipients were excluded. Additional inclusion and exclusion criteria and
information on the trial oversight, conduct, and
design are provided in the Supplementary Appendix, available with the full text of this article
at NEJM.org.
Trial Procedures

In both parts of the trial, the vaccination regimen
involved two doses of the mRNA-1273 vaccine or
saline placebo administered by intramuscular
(deltoid) injection 28 days apart. Part 1 of the
trial was designed to select a dose of mRNA-1273
vaccine for evaluation in part 2 (Fig. S1 in the
Supplementary Appendix). The safety and immunogenicity of the mRNA-1273 vaccine at a dose
level of 50 μg were evaluated in the 6-to-11-yearold age group before escalation to a 100-μg dose
level after review by the internal safety team. When
a prespecified subgroup of participants completed
day 57, an analysis was performed, and the 50-μg
dose level was selected by the sponsor and endorsed by the data and safety monitoring board.
In part 2 of the trial, children were randomly
assigned with the use of a centralized interactive
response technology system, in a 3:1 ratio, to receive two injections of the selected mRNA-1273
vaccine dose or placebo. The trial participants and
personnel were unaware of the trial-group assignments until the initiation of unblinding (on the
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date of the EUA); however, personnel who prepared and administered injections were aware of
these assignments.
The primary objectives were to determine the
safety and reactogenicity of two injections of the
selected dose of mRNA-1273 vaccine, administered
28 days apart, and to infer efficacy on the basis
of the noninferiority of serum antibody levels
and serologic response as compared with those
among young adults (18 to 25 years of age) from
the randomly selected immunogenicity subgroup
of the phase 3 COVE trial.1 Key secondary objectives were to determine the incidences of confirmed Covid-19 and SARS-CoV-2 infection (regardless of symptoms) after administration of
the mRNA-1273 vaccine or placebo (Table S1).
Safety

Evaluations of reactogenicity included assessment
of solicited local and systemic adverse reactions
that occurred within 7 days after each injection,
as recorded in electronic diaries by the parents or
guardians of the participants. Safety assessments
included the following: unsolicited adverse events
that occurred within 28 days after each injection
and adverse events leading to nonreceipt of the
second injection, discontinuation from the trial,
or both; medically attended adverse events, serious adverse events, and adverse events of special
interest, including MIS-C, myocarditis, and pericarditis; and SARS-CoV-2 infection assessed from
day 1 through trial completion. Enhanced surveillance of myocarditis (in part 2 of the trial) included solicitation of cardiac symptoms (safety
telephone calls) and medical follow-up and cardiac
assessment if indicated by the evaluating provider.
Immunogenicity

The geometric mean titers of neutralizing antibodies were measured with the use of a validated
lentivirus pseudovirus (D614G) assay with a 50%
inhibitory dilution (ID50) and an 80% inhibitory
dilution (ID80).1 Anti-spike geometric mean levels
of binding antibodies were measured with the use
of a Meso Scale Discovery assay (see the Supplementary Appendix). Serologic responses in participants were defined as an increase in antibody
titers from below the lower limit of quantitation
to titers that were at least 4 times the lower limit
of quantitation, or at least 4 times as high as the
baseline value if the baseline titers were equal to
or above the lower limit of quantitation. In part

1 of the trial, we also assessed the geometric
mean titers of neutralizing antibodies against the
B.1.617.2 (delta) variant.
Efficacy

In both parts 1 and 2 of the trial, the incidence of
confirmed symptomatic Covid-19 was defined in
accordance with the guidelines of the Centers
for Disease Control and Prevention (CDC). This
definition included one systemic or respiratory
symptom and a positive reverse-transcriptase–
polymerase-chain-reaction (RT-PCR) assay for
SARS-CoV-2. We also used the definition from
the phase 3 COVE trial involving adults; that
definition included at least two prespecified systemic symptoms or at least one respiratory symptom and a positive RT-PCR assay.1 SARS-CoV-2
infection (regardless of symptoms) was defined
by a negative SARS-CoV-2 status at baseline in
participants who later had a positive RT-PCR assay at a scheduled nasal-swab test or at a visit
prompted by SARS-CoV-2 symptoms or exposure
or by the detection of SARS-CoV-2–binding antibody levels against SARS-CoV-2 nucleocapsid protein measured by means of the Elecsys (Roche)
serologic assay at a scheduled postbaseline visit
(described in the protocol, available at NEJM.org).
Statistical Analysis

We planned to enroll up to 1275 participants in
the dose-selection cohorts in part 1 of the trial and
up to 12,000 participants (approximately 4000 per
age group) in part 2. Details regarding statistical
methods are provided in the Supplementary Methods section in the Supplementary Appendix, and
details regarding the analysis populations are provided in Table S2.
The safety population consisted of all the
participants who had received at least one trial
injection, and the solicited safety population consisted of those who had received at least one
injection and had at least one assessment for
solicited adverse events. Solicited adverse events
were evaluated according to trial and age group.
We summarized the numbers and percentages
of participants who had solicited adverse events
within 7 days after each injection according to
toxicity grade. We also summarized unsolicited
adverse events (presented according to the Medical
Dictionary for Regulatory Activities preferred terms
and system organ class categories), serious adverse events, medically attended adverse events,
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severe adverse events, and adverse events leading
to nonreceipt of the second injection or discontinuation from the trial. Descriptive summary data are
provided for all other safety measures.
For the primary objective of inference of mRNA1273 vaccine efficacy, we assessed the immunogenicity subgroups of children (6 to 11 years of age)
in this trial and young adults (18 to 25 years of
age) in a related phase 3 trial. The noninferiority
of geometric mean titers of neutralizing antibodies at day 57 in children as compared with
young adults was indicated if the lower boundary of the 95% confidence interval for the geometric mean titer ratio was at least 0.67 and if
the lower boundary of the 95% confidence interval for the difference in serologic response was
−10 percentage points or more (see the statistical analysis plan, which is included with the
protocol). We provide the geometric mean titers
and geometric mean ratios (with 95% confidence intervals calculated according to the analysis of covariance model), the number and percentage of participants with a serologic response
(with 95% confidence intervals calculated with
the Clopper–Pearson method), and the betweengroup difference in serologic response (with
95% confidence intervals calculated with the
Miettinen–Nurminen method) at day 57. The
same analysis was performed for binding-antibody values.
In part 2 of the trial, for the secondary efficacy objective of determining the incidences of
Covid-19 and SARS-CoV-2 infection, regardless
of symptoms, we evaluated all randomly assigned participants who did not have serologic
or virologic evidence of SARS-CoV-2 infection at
baseline and who received at least one planned
injection, excluding those who received an incorrect injection (the modified-intention-to-treat-1
population, hereafter called the mITT1 population) and those who received both injections of
trial vaccine according to the schedule, without
a major protocol deviation (the per-protocol
population). Incidence rates, which were calculated as the number of cases divided by the
number of person-years (defined as the total
years from the first day of the analysis to the
date of the event, to the last date of trial participation, to censoring time, or to the efficacy
data-cutoff date, whichever was earliest) accrued
during the blinded phase before unblinding, and
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95% confidence intervals were calculated with
the exact method (Poisson distribution).

R e sult s
Trial Population

Between March and August 2021, a total of 751
participants who were 6 to 11 years of age were
enrolled in part 1 of the trial and 4016 participants were enrolled in part 2. In part 1, all 380
participants who were enrolled in the 50-μg
dose-level mRNA-1273 group and 371 participants who were enrolled in the 100-μg doselevel mRNA-1273 group received one injection,
and 379 participants who were enrolled in the
50-μg dose-level group and 371 participants who
were enrolled in the 100-μg dose-level group
received two injections (Fig. S2).
In part 2 of the trial, 4016 participants were
randomly assigned to receive two 50-μg injections of the mRNA-1273 vaccine or two injections of placebo; 3005 participants in the vaccine
group and 997 participants in the placebo group
received the first injection, and 2988 participants
(99.2%) in the vaccine group and 973 participants
(96.9%) in the placebo group received both injections (Fig. 1). A total of 13 participants (0.4%) in
the vaccine group and 14 participants (1.4%) in
the placebo group did not receive the second
injection, most commonly because of withdrawal
of consent in both groups; 2 participants (0.2%)
in the placebo group received a vaccine that was
available under an EUA, outside the protocol. In
the vaccine group, 36 participants (1.2% of those
who received the first injection) discontinued the
trial, and these discontinuations were attributed
mainly to withdrawal of consent. In the placebo
group, 133 participants (13.3% of those who received the first injection) discontinued the trial;
these discontinuations were attributed mainly to
receipt of an EUA vaccine outside the protocol.
The demographic characteristics of the participants at baseline were generally balanced between
the trial groups, similar in parts 1 and 2 of the
trial, and representative of a diverse population
(Table 1 and Tables S3 and S4). In part 2, the
mean age of the participants in the safety population was 8.5 years (approximately 50% of the
participants were 6 to 8 years of age), 49.2% were
female, 51.9% were White non-Hispanic, and
47.9% were from communities of color. The dis-
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tribution of race groups included 65.6% White,
10.0% Black, 9.9% Asian, and 10.6% multiracial
participants, and 18.5% of the participants were
Hispanic or Latinx. Characteristics of the per-protocol immunogenicity subgroup in part 2 of the
trial, including representativeness of communities
of color, were generally similar to those in the
safety population in part 2 and those in the perprotocol immunogenicity subgroup in the COVE
trial involving young adults (18 to 25 years of age).
Safety

On the basis of the combined safety, reactogenicity, and immunogenicity results in part 1 of the
trial, the 50-μg dose level was selected for evaluation in the 6-to-11-year-old age group in part 2
(Part 1 Results section in the Supplementary Appendix). Data on safety are provided in Tables S5
through S10, and data on immunogenicity are
provided in Figures S3 and S4 and Tables S11
through S14.
In part 2 of the trial, the median duration of
follow-up was 82 days (interquartile range, 14 to
94) after the first injection and 51 days (interquartile range, 45 to 57) after the second injection.
Solicited local adverse events were more common
in the mRNA-1273 vaccine group than in the placebo group after the first injection (94% vs. 48%)
and after the second injection (95% vs. 51%); the
most common adverse event was injection-site
pain (Fig. 2A and Table S15). Most solicited local
adverse events after any injection were grades 1
or 2. In the mRNA-1273 group, the incidence of
local grade 3 adverse events was higher after the
second injection (4%) than after the first injection (2%).
The incidence of solicited systemic adverse
events after the first injection was similar in the
mRNA-1273 vaccine group (58%) and the placebo
group (52%) and higher after the second injection
in the mRNA-1273 vaccine group than in the
placebo group (in 78% vs. 50%) (Fig. 2B). In both
groups, the most common solicited systemic adverse events were headache and fatigue. In the
mRNA-1273 vaccine group, the incidences of chills
and fever were higher after the second injection
than after the first injection; these increases in
incidence were greater than the increases observed
with other adverse events. Most systemic adverse
events were grade 1 or 2. After the second injection, the incidence of systemic grade 3 adverse
events — most commonly fatigue, headache,

and fever — was higher in the mRNA-1273 group
(12%) than in the placebo group (1%).
The majority of solicited adverse events in the
vaccine group occurred within 1 or 2 days after
either injection and persisted for medians of 2 or
3 days. The median duration of fever was 1 day
(Table S16).
The incidences of local adverse events were
similar in children who received the mRNA-1273
vaccine at the 50-μg dose level and in young
adults (18 to 25 years of age) who received the
mRNA-1273 vaccine at the 100-μg dose level in
the COVE trial; the incidences of systemic adverse events were lower among the children than
among the young adults. The incidence of grade
3 adverse events was also lower in children than in
young adults, with the exception of fever, which
occurred more often in children than in young
adults after either injection, and in particular,
after the second injection (in 4% vs. 1%) (Tables
S17 and S18).
In the current trial, the incidence of unsolicited adverse events that occurred up to 28 days
after either injection was similar in the mRNA1273 vaccine group (29.6%) and the placebo group
(25.1%) (Tables S19 through S21). The incidence
of unsolicited adverse events that were considered
by the investigator to be related to the trial vaccine or placebo was higher in the mRNA-1273
group (10.6%) than in the placebo group (5.0%).
These events were mostly reactogenicity events;
injection-site erythema was the most common.
Serious unsolicited adverse events that occurred
up to 28 days after any injection were reported
for three participants (<0.1%) in the mRNA-1273
group and two participants (0.2%) in the placebo
group.
All serious adverse events in the mRNA-1273
vaccine group (appendicitis, cellulitis, and orbital
cellulitis) and in the placebo group (affective disorder and Covid-19) were considered by the investigators to be unrelated to the trial vaccine or
placebo. The incidence of medically attended
adverse events was similar in the mRNA-1273
group (13.4%) and the placebo group (14.2%).
No vaccination-related adverse events led to nonreceipt of the second injection, discontinuation
from the trial, or both. As of the data-cutoff date,
the investigators had not attributed any serious
adverse events to the trial vaccine or placebo,
and no deaths or cases of anaphylaxis, MIS-C,
myocarditis, or pericarditis were reported.
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4016 Children underwent randomization
(3:1)

3012 Were assigned to receive mRNA-1273
vaccine

1004 Were assigned to receive
placebo

7 Did not receive mRNA-1273
vaccine

7 Did not receive placebo

3005 Received the first injection

997 Received the first injection

14 Did not receive second
injection
2 Had adverse event
2 Were withdrawn by
physician
2 Received EUA vaccine
outside protocol
4 Withdrew consent
3 Entered open-label trial
or crossed over
1 Had other reason
10 Planned to cross over to
receive MRNA-1273
vaccine

13 Did not receive second
injection
1 Had adverse event
2 Were withdrawn by
physician
6 Withdrew consent
3 Entered open-label trial
1 Had other reason
4 Had planned but delayed
receipt of second injection
owing to illness or an
adverse event

2988 Received second injection

973 Received second injection

133 Discontinued trial
1 Was lost to follow-up
67 Received EUA vaccine
outside protocol
1 Was withdrawn by
physician
60 Withdrew consent
1 Had protocol deviation
3 Had other reason

36 Discontinued trial
1 Had adverse event
4 Were lost to follow-up
3 Were withdrawn by
physician
27 Withdrew consent
1 Had other reason

1907 Had data that remained blinded
1062 Had data that were unblinded and
continued in open-label trial

269 Had data that remained blinded
595 Had data that were unblinded and
continued in open-label trial
482 Had data that were unblinded and
received crossover first injection

2969 Continued in ongoing trial

864 Continued in ongoing trial

Efficacy

At day 57, the geometric mean titer of neutralizing antibodies was 1610 (95% CI, 1457 to 1780)
in 320 children who had received the mRNA-1273
vaccine at the 50-μg dose level as compared with
1300 (95% CI, 1171 to 1443) in 295 young adults
who had received the mRNA-1273 vaccine at the
6

100-μg dose level, with a serologic response in
at least 99% of the participants in both groups
(Tables 2 and S22 and Fig. S5). The geometric
mean titer ratio of neutralizing antibodies in
children as compared with young adults was 1.2
(95% CI, 1.1 to 1.4), and the between-group difference in the serologic response was 0.1 per-
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Figure 1 (facing page). Randomization and Analysis
Populations in Part 2 of the Trial.
The populations of trial participants (6 to 11 years of
age) who received the mRNA-1273 vaccine at a dose
level of 50 μg or placebo are shown. The reasons for
not receiving a first injection included withdrawal of
consent (in 8 participants), screening failure because
of error in randomization (in 5), and physician decision
owing to a medication change 1 month before consent
(in 1). Two participants who were randomly assigned to
receive placebo received the mRNA-1273 vaccine. In
the placebo group, the two adverse events were related
to coronavirus disease 2019 (Covid-19). In the mRNA1273 vaccine group, of the 36 participants who discontinued the trial, 9 had received a first injection and
27 had received a second injection. In the placebo
group, of the 133 participants who discontinued the
trial, 10 had received a first injection and 123 had received a second injection. The number of trial discontinuations includes 9 participants in the vaccine group
and 67 participants in the placebo group who had data
that were unblinded and discontinued the trial. After
October 29, 2021, the date of emergency use authorization (EUA) of the BNT162b2 vaccine for children 5 to
11 years of age, participants became eligible to have
their data unblinded. The cutoff date for blinded data
was November 10, 2021.

centage points (95% CI, −1.9 to 2.1), findings
that met the noninferiority criterion for the coprimary immunogenicity objective. These findings
were further supported by similar results with
respect to the distribution of binding antibodies
(Tables S23 and S24 and Fig. S6).
In the mITT1 population, among children
who did not have evidence of SARS-CoV-2 infection at baseline, the estimates of vaccine efficacy
at least 14 days after the first injection were 88.0%
(95% CI, 70.0 to 95.8) according to the CDC definition, with 7 cases (0.3%) in the mRNA-1273
group and 18 cases (2.1%) in the placebo group
and 91.8% (95% CI, 74.2 to 98.0) according to
the definition used in the phase 3 COVE trial involving adults, with 4 cases (0.1%) in the mRNA1273 group and 15 cases (1.7%) in the placebo
group (Fig. 3 and Table S25). The estimated vaccine efficacy against SARS-CoV-2 infection was
74.0% (95% CI. 57.9 to 84.1), regardless of symptoms that occurred at least 14 days after the first
injection, with 34 cases (1.3%) in the vaccine group
and 40 cases (4.6%) in the placebo group. The estimated vaccine efficacy against asymptomatic
SARS-CoV-2 infection was 62.5% (95% CI, 30.9
to 79.4), with 22 cases (2.5%) in the mRNA-1273
group and 27 cases (1.0%) in the placebo group.

The analysis of vaccine efficacy at least 14 days
after two injections (in the per-protocol population) was limited by the small number of Covid-19
cases and the shortened period of blinded followup (Table S26).
In part 1 of the trial, a preliminary analysis
showed an increase by a factor of 81.8 (95% CI,
70.4 to 95.0) in the geometric mean titer of neutralizing antibodies (ID50) against the delta variant
from baseline to day 57. A total of 99.3% of the
children had a serologic response, findings that
are similar to those indicated by increased geometric mean titers measured in adults who had
received a booster against this variant (Table S27).

Discussion
The ongoing KidCOVE trial to evaluate vaccination of children (6 to 11 years of age) with two
50-μg doses of the mRNA-1273 vaccine administered 28 days apart showed safety, immunogenicity, and vaccine efficacy that were consistent
with those previously observed in adolescents and
adults.1,2 These results extend the evidence of the
safety and efficacy of the mRNA-1273 vaccine
seen in adults and adolescents and provide support for the use of this vaccine to prevent Covid-19
in children.
A 50-μg dose level of the mRNA-1273 vaccine
was selected for evaluation in part 2 of the trial
on the basis of the lower reactogenicity than the
100-μg dose level and supportive immunogenicity
results in part 1. Dose levels of less than 50 μg
were not evaluated because of the risk of inferior
immunogenicity among children as compared
with that among young adults. In more than
3000 children who received at least one 50-μg
dose of the mRNA-1273 vaccine, no new safety
concerns were identified. Reactogenicity events
— most commonly injection-site pain, fatigue,
and headache — were generally mild to moderate. These events started within 1 or 2 days after
vaccination and resolved after 1 to 3 days. The
incidence of local adverse events was similar,
and the incidence of systemic adverse events was
lower in children 6 to 11 years of age than in
young adults (18 to 25 years of age) in the COVE
trial. The incidence of grade 3 adverse events, except for fever, was lower in children. The incidence
of fever, including grade 3 fever, was higher among
children than among young adults after any injection, with a median duration of 1 day; no febrile

n engl j med  nejm.org

7

The

n e w e ng l a n d j o u r na l

of

m e dic i n e

Table 1. Demographic and Clinical Characteristics in the Safety Population at Baseline (Part 2 of the Trial).*
Characteristic
Age — yr
Age category — no. (%)
6–8 yr
9–11 yr
Sex — no. (%)
Male
Female
Race or ethnic group — no. (%)†
White
Black
Asian
American Indian or Alaska Native
Native Hawaiian or Other Pacific Islander
Multiracial
Other race
Not reported
Unknown
Missing data
Hispanic or Latinx — no. (%)†
Yes
No
Not reported
Unknown
Race and ethnic group — no. (%)†
White non-Hispanic
Communities of color
Missing data
Weight — kg
Mean
Median (range)
Underlying conditions — no. (%)
Obesity‡
Chronic lung disease
Asthma
Cardiac disease
Diabetes mellitus
HIV infection
SARS-CoV-2 status — no. (%)§
Negative
Positive
Missing data

mRNA-1273, 50 μg
(N = 3007)

Placebo
(N = 995)

Total
(N = 4002)

8.5±1.7

8.5±1.6

8.5±1.7

1514 (50.3)
1493 (49.6)

484 (48.6)
511 (51.4)

1998 (49.9)
2004 (50.1)

1554 (51.7)
1453 (48.3)

481 (48.3)
514 (51.7)

2035 (50.8)
1967 (49.2)

1957 (65.1)
309 (10.3)
298 (9.9)
14 (0.5)
4 (0.1)
327 (10.9)
62 (2.1)
23 (0.8)
9 (0.3)
4 (0.1)

668 (67.1)
93 (9.3)
100 (10.1)
3 (0.3)
0
97 (9.7)
22 (2.2)
10 (1.0)
1 (0.1)
1 (0.1)

2625 (65.6)
402 (10.0)
398 (9.9)
17 (0.4)
4 (<0.1)
424 (10.6)
84 (2.1)
33 (0.8)
10 (0.2)
5 (0.1)

561 (18.7)
2417 (80.4)
22 (0.7)
7 (0.2)

181 (18.2)
805 (80.9)
5 (0.5)
4 (0.4)

742 (18.5)
3222 (80.5)
27 (0.7)
11 (0.3)

1542 (51.3)
1459 (48.5)
6 (0.2)

536 (53.9)
456 (45.8)
3 (0.3)

2078 (51.9)
1915 (47.9)
9 (0.2)

33.3±11.3
30.6 (14.0–112.0)

33.5±11.4
30.9 (14.2–99.8)

33.4±11.3
30.7 (14.0–112.0)

608 (20.2)
279 (9.3)
250 (8.3)
19 (0.6)
9 (0.3)
4 (0.1)

195 (19.6)
90 (9.0)
83 (8.3)
7 (0.7)
5 (0.5)
0

803 (20.1)
369 (9.2)
333 (8.3)
26 (0.6)
14 (0.3)
4 (<0.1)

2703 (89.9)
257 (8.5)
47 (1.6)

880 (88.4)
87 (8.7)
28 (2.8)

3583 (89.5)
344 (8.6)
75 (1.9)

*	Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. HIV denotes human immunodeficiency virus, and
SARS-CoV-2 severe acute respiratory syndrome coronavirus 2.
†	Race and ethnic group were reported by the participants or by their parents or guardians. Participants could be included in more than one
category. Race and ethnic group categories shown are White (non-Hispanic) and communities of color (i.e., White Hispanic participants,
non-White participants, all others whose race or ethnic group was reported as not known, not reported, or missing).
‡	Obesity was defined as a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) at or above the 95th
percentile according to the revised World Health Organization Child Growth Standards.
§	Baseline SARS-CoV-2 status was positive if there was immunologic or virologic evidence of previous Covid-19, as defined by a positive reverse transcriptase–polymerase-chain-reaction (RT-PCR) test or a positive immunoassay result (i.e., detection of binding antibodies against the SARS-CoV-2
nucleocapsid [Elecsys, Roche] above the limit of detection or the lower limit of quantification at day 1). Baseline SARS-CoV-2 status was negative if
there was a negative RT-PCR test and a negative immunoassay result (i.e., no detection of binding antibodies against the SARS-CoV-2 nucleocapsid [Elecsys, Roche] below the limit of detection and the lower limit of quantitation at day 1). The data-cutoff date was November 10, 2021.
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Figure 2. Solicited Local and Systemic Adverse Reactions in Part 2 of the Trial.
Shown is the percentage of participants in the solicited safety population who had a solicited local or systemic adverse reaction within
7 days after the first or second 50-μg injection of the mRNA-1273 vaccine or placebo. The numbers above the bars are the percentage
of participants in each group with the specified reaction. Lymphadenopathy was defined as axillary or groin swelling or tenderness. The
data-cutoff date was November 10, 2021.

seizures were reported. Analysis of all safety data,
including unsolicited adverse events, identified no
short-term safety issues. No deaths, anaphylaxis
events, MIS-C, myocarditis, pericarditis, or vaccinerelated serious adverse events were reported
through the data-cutoff date.
The efficacy of the 50-μg dose level of the
mRNA-1273 vaccine in children in this trial was

inferred by successful immunobridging to data
in young adults who had received the 100-μg
dose level of the vaccine in the COVE trial, which
had shown high efficacy.1 Moreover, the magnitude of the geometric mean titer of neutralizing
antibodies ID50 (1610, or 390 IU per milliliter) at
day 57 was comparable to that of titers (high
tertile; >363 IU per milliliter) that correlated
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Table 2. Immunogenicity of the mRNA-1273 Vaccine in Part 2 of the Trial.*
Children, 6–11 Yr
mRNA-1273, 50 μg
(N = 320)

Variable

Young Adults, 18–25 Yr
mRNA-1273, 100 μg
(N = 295)

Children vs. Young Adults

Baseline
No. of participants with nonmissing data

317

295

Geometric mean pseudovirus neutralizing antibody titer (95% CI)†

9.3 (NE to NE)

9.3 (9.2 to 9.4)

No. of participants with nonmissing data

319

295

Geometric mean pseudovirus neutralizing antibody titer (95% CI)‡

1610 (1457 to 1780)

1300 (1171 to 1443)

Geometric mean titer ratio, 1.2
(95% CI, 1.1 to 1.4)‡

313/316 (99.1)

292/295 (99.0)

0.1 percentage points
(95% CI, −1.9 to 2.1)¶

97.3 to 99.8

97.1 to 99.8

Day 57

Serologic response
No. of participants/total no. (%)§
95% CI‖

*	The 50% inhibitory dilution titer of neutralizing antibodies was determined for participants in the immunogenicity population. For neutralizing antibody values that were assessed by pseudovirus neutralizing antibody assay and reported as being below the lower limit of
quantitation (18.5), 0.5 times the lower limit of quantitation was used in the analysis. For values greater than the upper limit of quantitation (45,118), the upper limit of quantitation was used in the analysis if actual values were not available. The young adults group includes
participants who were 18 to 25 years of age in the mRNA-1273 group in the COVE trial. The upper limit of quantitation was different for
selected COVE trial participants who had undergone testing previously. The data-cutoff date was November 10, 2021. To convert the values
for geometric mean pseudovirus neutralizing antibody titers to international units, multiply by 0.242.
†	The 95% confidence intervals were calculated with the use of t-distribution of the log-transformed values for geometric mean titer (observed
or model-based, which is estimated by geometric least-squares means), respectively, then back-transformed to the original scale for presentation.
‡	The log-transformed antibody levels were analyzed with the use of an analysis of covariance model (primary approach) with the group
variable (children and young adults in the COVE trial) as a fixed effect. The resulting least-squares means, the difference of least-squares
means, and 95% confidence intervals were back-transformed to the original scale for presentation.
§	The serologic response in participants was defined as an increase in antibody titers from below the lower limit of quantitation to titers that
were at least 4 times the lower limit of quantitation, or at least 4 times as high as the baseline value if the baseline titers were equal to or
above the lower limit of quantitation. Percentages were based on the number of participants with nonmissing data at baseline and the corresponding time point.
¶	The 95% confidence interval was calculated with the use of the confidence limits in the Miettinen–Nurminen method.
‖	The 95% confidence interval was calculated with the use of the Clopper–Pearson method.

with a 69% Covid-19 risk reduction in the COVE
trial.17 These results indicate that vaccinated children who are 6 to 11 years of age may be protected from Covid-19 and subsequent sequelae.
The low incidences of Covid-19 and SARSCoV-2 infections were expected given the limited
blinded follow-up period and 3:1 (mRNA-1273:
placebo) randomization. Nevertheless, the mRNA1273 vaccine at a dose level of 50 μg in children
was protective against Covid-19 beginning 14 days
after the first injection (in the mITT1 population),
as assessed either by the less-stringent CDC criteria (reflecting the milder cases of Covid-19 among
children) or the COVE trial definitions. This vaccine was also protective against SARS-CoV-2 infection regardless of symptoms or asymptomatic
infection. These findings were consistent with the
vaccine efficacy observed in the COVE trial involv10

ing adults and the Teen COVE trial involving adolescents.1,2
Our trial showed the efficacy of mRNA-1273
vaccine when delta was the predominant circulating variant and provided preliminary results
indicating that in children mRNA-1273 vaccine
elicits neutralizing antibody responses that are
similar to those observed against the delta variant
after booster vaccination in adults. These findings
suggest that this vaccine provides a protective benefit for children against variants of concern. Our
findings are also consistent with those reported
in other studies showing the effectiveness of
mRNA-1273 vaccine in reducing Covid-19–related
hospital admissions during the circulation of the
delta variant5 and the neutralization of variants18-20,
including the B.1.1.529 (omicron) variant, after
vaccination in children and adolescents.21-23

n engl j med  nejm.org

The m RNA-1273 Vaccine in Children 6 to 11 Years
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Figure 3. Vaccine Efficacy after the First Injection in Part 2 of the Trial.
The cumulative incidence of Covid-19 was based on the Centers for Disease Control and Prevention (CDC) definition (Panel A) and the
primary case definition in the COVE trial (Panel B) in the modified-intention-to-treat-1 population, 14 days after the first injection.
Covid-19 cases are based on one symptom according to the CDC definition and two symptoms in the primary case definition used in
the COVE trial.1 The number of person-years was defined as the total years from the first day of the analysis to the date of the event, to
the last date of trial participation, to censoring time, or to the efficacy data-cutoff date, whichever was earliest. Incidence was defined as
the number of participants with an event divided by the number of participants at risk, with adjustment for person-years (total time at
risk) in each trial group. The 95% confidence interval (CI) was calculated with the use of the exact method (Poisson distribution) with
adjustment for person-years. Vaccine efficacy was defined as 1 minus the ratio of the incidence rate (mRNA-1273 vaccine vs. placebo),
and the 95% confidence interval of the ratio was calculated with the use of the exact method conditional on the total number of cases,
with adjustment for person-years. The data-cutoff date was November 10, 2021. The insets show the same data on an expanded y axis.
Tick marks in both panels indicate censored data.

The diversity of enrolled participants in this
large trial, which was similar to that in the COVE
trial,1 reflects the generalizability of the results to
various populations of children. The limitations
of the trial data include a lack of long-term results.
Data from the 1-year follow-up after the second
injection are being evaluated to assess the safety

of the mRNA-1273 vaccine and the durability of
its protection in children.24,25 Owing to the few
cases of Covid-19 that occurred during the short,
blinded phase of the trial, evaluation of the efficacy of mRNA-1273 after two injections was
limited when the number of cases would be expected to be higher; nonetheless, the efficacy ob-

n engl j med  nejm.org

11

The

n e w e ng l a n d j o u r na l

served after one injection is reassuringly similar
to that seen in adolescents and adults who have
received mRNA-1273.1,2 Although the trial was
powered to assess the safety of rare events (0.1%),
even rarer events were identified during the global
distribution of Covid-19 vaccines; thus, continued
vigilance in monitoring safety is warranted.26
The effectiveness of the mRNA-1273 vaccine
in the trial shown during the delta variant outbreak in the United States and preliminary results
that show neutralization of the delta variant suggest that the vaccine can provide a protective benefit in children against variants, findings that are
consistent with those of other studies.18-22 However, the trial was conducted before the surge of
the omicron variant, and assessment of the benefit of the vaccine against this variant is ongoing
in the trial.
The trial results indicate that a 50-μg dose
level of the mRNA-1273 vaccine had an acceptable
safety profile and was efficacious in children 6 to
11 years of age. The trial is ongoing to provide additional safety and efficacy data in this age group
as well as in younger children (6 months to 5 years

of

m e dic i n e

of age). Vaccination of children may help to protect
them from Covid-19 and may reduce community
circulation of SARS-CoV-2 variants and lead to a
return toward normal routines.
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